In vitro-targeted gene identification in patients with hepatitis C using a genome-wide microarray technology

Hepatology

Volumn 49, Issue 2, 2009, Pages 378-386

  Hagist, Susanne ^a   Sültmann, Holger ^b   Millonig, Gunda ^a   Hebling, Ulrike ^a   Kieslich, Dörthe ^a   Kuner, Rupert ^b   Balaguer, Sabrina ^b   Seitz, Helmut Karl ^a   Poustka, Annemarie ^b   Mueller, Sebastian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TROPOMYOSIN; ANAPHASE PROMOTING COMPLEX; B LYMPHOCYTE GROWTH FACTOR; CANNABINOID 1 RECEPTOR; COMPLEMENTARY DNA; DICKKOPF 1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON REGULATORY FACTOR; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR B; PHOSPHODIESTERASE IV; PROTEIN TYROSINE PHOSPHATASE; REACTIVE OXYGEN METABOLITE; SODIUM PHOSPHATE COTRANSPORTER 1; TRANSMEMBRANE CONDUCTANCE REGULATOR; TYROSINE; VASCULOTROPIN; ATRIAL NATRIURETIC FACTOR RECEPTOR; HIF1A PROTEIN, HUMAN; IRON; MESSENGER RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA MICROARRAY; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IRON STORAGE; MICROARRAY ANALYSIS; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; DISEASE COURSE; GENETICS; HEMOCHROMATOSIS; HUMAN GENOME; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED;

ADULT; DISEASE PROGRESSION; DNA, COMPLEMENTARY; GENOME, HUMAN; HEMOCHROMATOSIS; HEPATITIS C; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON; LIVER CIRRHOSIS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REACTIVE OXYGEN SPECIES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 61949276507     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22677     Document Type: Article

References (42)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
2. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-1313.
3. Barbaro G, Di Lorenzo G, Asti A, Ribersani M, Belloni G, Grisorio B, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: Ultrastructural and biochemical findings. Am J Gastroenterol 1999;94:2198-2205.
4. Valgimigli M, Valgimigli L, Trere D, Gaiani S, Pedulli GF, Gramantieri L, et al. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic Res 2002;36:939-948.
5. Ibrahim NO, Hahn T, Franke C, Stiehl DP, Wirthner R, Wenger RH, et al. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. Cancer Res 2005;65:11094-11100.
6. Mueller S, Afdhal NH, Schuppan D. Iron, HCV, and liver cancer: Hard metal setting the pace? Gastroenterology 2006;130:2229-2234.
7. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366-375.
8. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 2001;98:9599-9604.
9. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127:S79-S86.
10. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 2000;95:1041-1050.
11. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995;22:449-456.
12. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102: 2108-2113.
13. Haque S, Chandra B, Gerber MA, Lok AS. Iron overload in patients with chronic hepatitis C: A clinicopathologic study. Hum Pathol 1996;27:1277-1281.
14. Ko C, Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, et al. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: Results from the National Hemochromatosis Transplant Registry. Liver Int 2007;27:1394-1401.
15. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: Molecular control of mammalian iron metabolism. Cell 2004;117:285-297.
16. Feld JJ, Liang TJ. Hepatitis C - identifying patients with progressive liver injury. HEPATOLOGY 2006;43:S194-S206.
17. Furutani T, Hino K, Okuda M, Gondo T, Nishina S, Kitase A, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006;130: 2087-2098.
18. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron effiux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
19. Laftah AH, Sharma N, Brookes MJ, McKie AT, Simpson RJ, Iqbal TH, et al. Tumour necrosis factor alpha causes hypoferraemia and reduced intestinal iron absorption in mice. Biochem J 2006;397:61-67.
20. Aoki CA, Rossaro L, Ramsamooj R, Brandhagen D, Burritt MF, Bowlus CL. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol 2005;39:71-74.
21. Takeo M, Kobayashi Y, Fujita N, Urawa N, Iwasa M, Horiike S, et al. Upregulation of transferrin receptor 2 and ferroportin 1 mRNA in the liver of patients with chronic hepatitis C. J Gastroenterol Hepatol 2005;20:562-569.
22. Mueller S, Pantopoulos K, Hübner CA, Stremmel W, Hentze MW. IRP1 activation by extracellular oxidative stress in the perfused rat liver. J Biol Chem 2001;276:23192-23196.
23. Andriopoulos B, Hegedusch S, Mangin J, Riedel HD, Hebling U, Wang J, et al. Sustained hydrogen peroxide induces iron uptake by transferrin receptor-1 independent of the iron regulatory protein/iron-responsive element network. J Biol Chem 2007;282:20301-20308.
24. Jayapal M, Melendez AJ. DNA microarray technology for target identification and validation. Clin Exp Pharmacol Physiol 2006;33:496-503.
25. Barton MC, Stivers DN. Microarray analysis of hepatic-regulated gene expression: Specific applications and nonspecific problems. HEPATOLOGY 2002;35:727-729.
26. Girard S, Vossman E, Misek DE, Podevin P, Hanash S, Brechot C, et al. Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. HEPATOLOGY 2004;40: 708-718.
27. Kuner R, Vogt M, Sultmann H, Buness A, Dymalla S, Bulkescher J, et al. Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses. J Mol Med 2007;85:1253-1262.
28. Larsson O, Wahlestedt C, Timmons JA. Considerations when using the significance analysis of microarrays (SAM) algorithm. BMC Bioinformatics 2005;6:129.
29. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
30. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005;105:659-669.
31. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993;82:3610-3615.
32. Mueller S. Iron regulatory protein 1 as a sensor of reactive oxygen species. Biofactors 2005;24:171-181.
33. Grigoryev DN, Ma SF, Shimoda LA, Johns RA, Lee B, Garcia JG. Exon-based mapping of microarray probes: Recovering differential gene expression signal in underpowered hypoxia experiment. Mol Cell Probes 2007; 21:134-139.
34. Kovacevic Z, Richardson DR. The metastasis suppressor, Ndrg-1: A new ally in the fight against cancer. Carcinogenesis 2006;27:2355-2366.
35. Hansen L, Pedersen O. Genetics of type 2 diabetes mellitus: Status and perspectives. Diabetes Obes Metab 2005;7:122-135.
36. Degols G, Eldin P, Mechti N. ISG20, an actor of the innate immune response. Biochimie 2007;89:831-835.
37. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. HEPATOLOGY 2007;46: 1548-1563.
38. Sakita-Suto S, Kanda A, Suzuki F, Sato S, Takata T, Tatsuka M. Aurora-B regulates RNA methyltransferase NSUN2. Mol Biol Cell 2007;18:1107-1117.
39. Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K, et al. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 2006;12:568-573.
40. Han SJ, Lee JS, Kang JS, Kim YJ. Med9/Cse2 and Gal11 modules are required for transcriptional repression of distinct group of genes. J Biol Chem 2001;276:37020-37026.
41. Han SJ, Lee YC, Gim BS, Ryu GH, Park SJ, Lane WS, et al. Activator-specific requirement of yeast mediator proteins for RNA polymerase II transcriptional activation. Mol Cell Biol 1999;19:979-988.
42. Schneider J, Buness A, Huber W, Volz J, Kioschis P, Hafner M, et al. Systematic analysis of T7 RNA polymerase based in vitro linear RNA amplification for use in microarray experiments. BMC Genomics 2004;5:29.